# A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.

> **NCT05568706** · PHASE2 · COMPLETED · sponsor: **Enanta Pharmaceuticals, Inc** · enrollment: 186 (actual)

## Conditions studied

- RSV Infection

## Interventions

- **DRUG:** EDP-938
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05568706
- **Lead sponsor:** Enanta Pharmaceuticals, Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-29
- **Primary completion:** 2025-06-23
- **Final completion:** 2025-06-23
- **Target enrollment:** 186 (ACTUAL)
- **Last updated:** 2025-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05568706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05568706, "A Study of EDP-938 in Non-hospitalized Adults With RSV Who Are at High Risk for Complications.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05568706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*